SCHEMBL150480

SCHEMBL150480

NC(=O)c1cccc2c1[nH]c1cc(NC(=O)C(O)c3ccccc3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 8/20 0.43
BTK Q06187 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
JAK1 P23458 4/20 0.40
TYK2 P29597 4/20 0.40
JAK3 P52333 4/20 0.40
MAOA P21397 1/20 0.38
EIF2S1 P05198 1/20 0.38
EIF2AK3 Q9NZJ5 1/20 0.38
KIF11 P52732 1/20 0.37
MAPK14 Q16539 1/20 0.37
F9 P00740 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27998034 0.84 JAK2 (0.47) JAK2BTKKDM4EMEN1CYP1A2
SCHEMBL146141 0.77 JAK2 (0.51) JAK2BTKKDM4EPIM1PIM3
SCHEMBL148108 0.74 AURKA (0.48) JAK2BTKKDM4EMEN1CYP1A2
SCHEMBL150223 0.73 CHUK (0.49) JAK2ROCK2
SCHEMBL145574 0.72 PIM3 (0.65) JAK2TDP1PIM1PIM3KIF11
SCHEMBL29605233 0.72 PIM3 (0.65) JAK2TDP1PIM1PIM3KIF11
SCHEMBL149424 0.72 ROCK2 (0.58) JAK2ROCK2
SCHEMBL148318 0.72 PIM1 (0.50) JAK2BTKKDM4EMEN1KMT2A
SCHEMBL151157 0.72 NPY5R (0.47) JAK2ROCK2
Hydrochloric Acid SCHEMBL28848226 0.71 PIM3 (0.63) JAK2TDP1PIM1PIM3KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 JAK2 13/4885BTK 1/4885KDM4E 733/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 JAK2 13/4885BTK 1/4885KDM4E 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.